Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 5:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 273 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Factor VIII (FVIII) Protein Clear all
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A

NCT01458106
View directory record Official record
Conditions
Hemophilia A
Interventions
BIIB031 (rFVIIIFc), FVIII (PK subgroup only)
Drug
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
Up to 11 Years · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
12
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 28, 2026, 5:06 PM EDT
Completed No phase listed Observational

Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A

NCT02035384
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A
Interventions
turoctocog alfa
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Male only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
6
States / cities
Mobile, Alabama • Torrance, California • Peoria, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2020 · Synced Sep 28, 2026, 5:06 PM EDT
Recruiting Phase 4 Interventional

Hemlibra in Mild Hemophilia A

NCT04567511
View directory record Official record
Conditions
Factor VIII Deficiency, Congenital
Interventions
Emicizumab
Drug
Lead sponsor
Indiana Hemophilia &Thrombosis Center, Inc.
Other
Eligibility
5 Years to 45 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 14, 2024 · Synced Sep 28, 2026, 5:06 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults

NCT04370054
View directory record Official record
Conditions
Hemophilia A
Interventions
PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
19
States / cities
Mountain View, California • Oakland, California • Palo Alto, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 28, 2026, 5:06 PM EDT
Active, not recruiting No phase listed Observational

Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A

NCT03932201
View directory record Official record
Conditions
Hemophilia A
Interventions
Damoctocog alfa pegol (Jivi, Bay94-9027)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Not listed
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
10
States / cities
Mobile, Alabama • Phoenix, Arizona • Davis, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A

NCT02093897
View directory record Official record
Conditions
Congenital Hemophilia A
Interventions
rVIII-SingleChain
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
Up to 11 Years · Male only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Aurora, Colorado • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Sep 28, 2026, 5:06 PM EDT
Active, not recruiting Phase 3 Interventional

A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors

NCT05135559
View directory record Official record
Conditions
Haemophilia A and B With and Without Inhibitors
Interventions
Concizumab
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
19
States / cities
San Diego, California • Aurora, Colorado • Orlando, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors

NCT02847637
View directory record Official record
Conditions
Hemophilia A
Interventions
Emicizumab, Factor VIII (FVIII)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
8
States / cities
Santa Monica, California • Washington D.C., District of Columbia • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Sep 28, 2026, 5:06 PM EDT
Recruiting No phase listed Observational

Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients

NCT03695978
View directory record Official record
Conditions
Haemophilia A
Interventions
Not listed
Lead sponsor
Octapharma
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
5
States / cities
Miami, Florida • New Orleans, Louisiana • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 28, 2026, 5:06 PM EDT
Terminated Phase 2 Interventional

The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

NCT05789524
View directory record Official record
Conditions
Hemophilia a, Hemophilia B
Interventions
SerpinPC
Drug
Lead sponsor
ApcinteX Ltd
Industry
Eligibility
12 Years to 65 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Aurora, Colorado • Tampa, Florida • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Phase 1 Interventional

Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers

NCT02506023
View directory record Official record
Conditions
Hemophilia A
Interventions
Desmopressin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 15, 2018 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Phase 2 Interventional Results available

A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia A

NCT03061201
View directory record Official record
Conditions
Hemophilia A
Interventions
SB-525 (PF-07055480)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
22
States / cities
Little Rock, Arkansas • Duarte, California • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 28, 2026, 5:06 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A

NCT07220564
View directory record Official record
Conditions
Haemophilia A
Interventions
NNC0442-0344 A
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
5
States / cities
Aurora, Colorado • Indianapolis, Indiana • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Phase 1 Interventional

A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B

NCT01708564
View directory record Official record
Conditions
Hemophilia
Interventions
rhFVIIa
Biological
Lead sponsor
rEVO Biologics
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Sacramento, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Sep 28, 2026, 5:06 PM EDT
Terminated No phase listed Observational

Host Genetic Factors Influencing HIV1 and HCV Viral Loads and AIDS Clinical Progression in a Hemophilia Cohort (HGDS-3)

NCT00340548
View directory record Official record
Conditions
Hemophilia, AIDS
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Years to 100 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2020
U.S. locations
15
States / cities
La Jolla, California • Los Angeles, California • Indianapolis, Indiana + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 28, 2026, 5:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Motor Proficiency of People With Bleeding Disorders Using the BOT-2 (TM)

NCT02279199
View directory record Official record
Conditions
Hemophilia
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
4 Years to 21 Years · Male only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Sep 28, 2026, 5:06 PM EDT
Withdrawn Phase 3 Interventional

Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform

NCT02196207
View directory record Official record
Conditions
Severe Hemophilia A
Interventions
Eloctate Prophylaxis, Emicizumab Prophylaxis, Eloctate ITI plus Emicizumab, Eloctate ITI
Drug
Lead sponsor
Margaret Ragni
Other
Eligibility
4 Months to 99 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Sep 28, 2026, 5:06 PM EDT
Terminated Phase 3 Interventional Results available

The Hemophilia Inhibitor Eradication Trial

NCT04303572
View directory record Official record
Conditions
Hemophilia A With Inhibitor
Interventions
Eloctate ITI, Emicizumab
Drug
Lead sponsor
Margaret Ragni
Other
Eligibility
Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of BAX 888 in Male Adults With Severe Hemophilia A

NCT03370172
View directory record Official record
Conditions
Hemophilia A
Interventions
BAX 888
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
8
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Phase 2 Interventional

Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII

NCT00245245
View directory record Official record
Conditions
Hemophilia A
Interventions
recombinant porcine coagulation factor VIII (OBI-1)
Drug
Lead sponsor
Octagen Corporation
Industry
Eligibility
12 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Blue Bell, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 3, 2007 · Synced Sep 28, 2026, 5:06 PM EDT
Not listed Phase 3 Interventional

Safety and Efficacy Extension Study of GreenGene™ F in Previously Treated Patients Diagnosed With Severe Hemophilia A

NCT02027779
View directory record Official record
Conditions
Hemophilia A
Interventions
GreenGene™ F
Biological
Lead sponsor
Green Cross Corporation
Industry
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Little Rock, Arkansas • New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Sep 28, 2026, 5:06 PM EDT
Recruiting Phase 4 Interventional

SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors

NCT04647227
View directory record Official record
Conditions
Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
Interventions
coagulation factor VIIa [recombinant]-jncw
Drug
Lead sponsor
American Thrombosis and Hemostasis Network
Network
Eligibility
12 Years to 100 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
21
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Phase 1Phase 2 Interventional

Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors

NCT04684940
View directory record Official record
Conditions
Hemophilia A With Inhibitor, Hemophilia A With Anti Factor VIII
Interventions
Valoctocogene roxaparvovec
Biological
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 28, 2026, 5:06 PM EDT
Completed Phase 4 Interventional Results available

Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies

NCT03103542
View directory record Official record
Conditions
Hemophilia A
Interventions
Recombinant coagulation factor (rFVIIIFc)
Biological
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 28, 2026, 5:06 PM EDT